Cardiff Oncology, Inc. (CRDF)
| Market Cap | 73.13M -50.3% |
| Revenue (ttm) | 508,000 -6.8% |
| Net Income | -40.08M |
| EPS | -0.59 |
| Shares Out | 77.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 528,695 |
| Open | 0.9903 |
| Previous Close | 0.9861 |
| Day's Range | 0.9335 - 0.9941 |
| 52-Week Range | 0.7566 - 3.3100 |
| Beta | 1.44 |
| Analysts | Buy |
| Price Target | 5.10 (+442.55%) |
| Earnings Date | Aug 11, 2026 |
About CRDF
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CR... [Read more]
Financial Performance
In 2025, Cardiff Oncology's revenue was $593,000, a decrease of -13.18% compared to the previous year's $683,000. Losses were -$45.88 million, 0.93% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for CRDF stock is "Buy." The 12-month stock price target is $5.1, which is an increase of 442.55% from the latest price.
News
Cardiff Oncology Proxy statement: Proxy filing
Cardiff Oncology filed a proxy statement on August 26, 2026, providing details for shareholder voting and corporate governance matters.
Cardiff Oncology Proxy statement: Proxy filing
Cardiff Oncology filed a proxy statement on August 26, 2026, providing details for shareholder voting and corporate governance matters.
Cardiff Oncology reports Q2 EPS (14c), consensus (16c)
Reports Q2 revenue $104,000, consensus $62,780. “The second quarter was an important period of progress for Cardiff, highlighted by the presentation of positive Phase 2 data at ASCO and our…
Cardiff Oncology downgraded to Market Perform from Outperform at William Blair
William Blair downgraded Cardiff Oncology (CRDF) to Market Perform from Outperform. Post-Q2 results, the firm said the company’s fundamentals have deteriorated materially. The firm added that it belie...
Cardiff Oncology Proxy statement: Proxy filing
Cardiff Oncology filed a proxy statement on August 14, 2026, providing details for shareholder voting and corporate governance matters.
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCR...
Cardiff Oncology Quarterly report: Q2 2026
Cardiff Oncology has published its Q2 2026 quarterly earnings report on August 11, 2026.
Cardiff Oncology Earnings release: Q2 2026
Cardiff Oncology released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Cardiff Oncology announces $10M registered direct offering
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Cardiff Oncology Announces $10 Million Registered Direct Offering
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (the “Company”), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies,...
Cardiff Oncology price target lowered to $4 from $10 at Lucid Capital
Lucid Capital analyst Christopher Liu lowered the firm’s price target on Cardiff Oncology (CRDF) to $4 from $10 and keeps a Buy rating on the shares. The company’s licensor dispute…
Cardiff Oncology Transcript: Jefferies Global Healthcare Conference 2026
Onvansertib, a PLK1 inhibitor, is advancing to a global phase III trial in frontline RAS-mutated metastatic colorectal cancer after strong phase II results, with FDA support and robust enthusiasm from clinicians. The agent is well-tolerated and positioned to address a major unmet need, while the company navigates an ongoing IP dispute.
Craig-Hallum downgrades Cardiff Oncology to Hold, lowers target to $2
As previously reported, Craig-Hallum downgraded Cardiff Oncology (CRDF) to Hold from Buy with a price target of $2, down from $10. The firm notes the company presented an update from…
Cardiff Oncology downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum downgraded Cardiff Oncology (CRDF) to Hold from Buy with a $2 price target
Cardiff Oncology Transcript: Status update
Promising phase II results show 30 mg onvansertib plus FOLFIRI-BEV achieves a 72% ORR and durable responses in first-line RAS-mutated mCRC, with a favorable safety profile and consistent efficacy across subgroups. Phase III trial design is FDA-aligned, aiming for both accelerated and full approval.
Cardiff Oncology Press release: Status update
Cardiff Oncology issued a press release on June 3, 2026, disclosing material business information to investors.
Cardiff Oncology Slides: Status update
Cardiff Oncology has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
Cardiff Oncology announces results from CRDF-004 trial
Cardiff Oncology (CRDF) announced results from CRDF-004, a randomized, controlled, dose-finding Phase 2 clinical trial evaluating onvansertib in combination with SoC regimens in patients with first-li...
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
- The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program -
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance...
Cardiff Oncology downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Robert Burns downgraded Cardiff Oncology (CRDF) to Neutral from Buy without a price target after the company disclosed that Nerviano Medical Sciences was terminating the licens...
Cardiff Oncology says NMS terminating license agreement
In a regulatory filing, Cardiff Oncology (CRDF) said: “As previously disclosed, on May 19, Cardiff Oncology filed a lawsuit against Nerviano Medical Sciences disputing NMS’s allegation that the Compan...
Cardiff Oncology downgraded to Hold from Buy at TD Cowen
TD Cowen downgraded Cardiff Oncology (CRDF) to Hold from Buy with no price target after the company disclosed that onvansertib’s orginator Nerviano Medical Sciences has alleged that Cardiff has breach...
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
Updated Phase 2 CRDF-004 data to be presented during ASCO 2026 rapid oral session on June 2, 2026; investor webcast scheduled for June 3, 2026 at 8:30 am ET to review the data Updated Phase 2 CRDF-004...
Cardiff Oncology reports Q1 EPS (18c), consensus (12c)
“This quarter was marked by the positive data update from our randomized Phase 2 CRDF-004 trial of onvansertib in first-line RAS-mutated metastatic colorectal cancer, along with key leadership additio...